Which genomic mutations should be tested in a patient with metastatic triple‑negative breast cancer who is not tolerating sacituzumab well?

Genomic Testing for Metastatic Triple-Negative Breast Cancer with Sacituzumab Intolerance

Test for germline BRCA1/2 mutations, PD-L1 expression, and consider comprehensive next-generation sequencing (NGS) to identify actionable mutations that can guide alternative targeted therapies when sacituzumab is not tolerated.

Priority Testing Algorithm

First-Line Essential Tests

1. Germline BRCA1/2 Testing

• This is the highest priority mutation test for metastatic triple-negative breast cancer (mTNBC) patients who cannot continue sacituzumab 1.
• BRCA1/2 mutations determine eligibility for PARP inhibitors (olaparib or talazoparib), which have demonstrated significant clinical benefit in this population 1.
• Approximately 95% of actionable mutations can be identified through comprehensive genomic profiling 2.
• Note: While germline BRCA1/2 status does not predict sacituzumab response (no significant PFS or OS difference between carriers and wild-type patients) 3, it is critical for identifying alternative treatment options.

2. PD-L1 Expression Testing

• Required for pembrolizumab eligibility in hormone receptor-negative, HER2-negative mTNBC 1.
• Must use FDA-approved testing methodology.
• Pembrolizumab plus chemotherapy is an established option for PD-L1-positive disease.

Second-Line Comprehensive Testing

3. Next-Generation Sequencing (NGS) Panel

• Perform comprehensive tumor NGS early, preferably while the patient still has good performance status 2.
• The 2024 ESMO guidelines recommend tumor NGS as standard of care for metastatic breast cancer after endocrine therapy resistance 4.

Key actionable mutations to identify in mTNBC:

• PIK3CA mutations: May respond to PI3K inhibitors or AKT pathway inhibitors (capivasertib) 4
• NTRK fusions: Determine eligibility for larotrectinib or entrectinib 1
• TMB-high status (≥10 mutations/megabase): Predicts response to pembrolizumab monotherapy 1, 5
• MSI-H/dMMR: Qualifies for dostarlimab or pembrolizumab 1
• PALB2 germline variants: Emerging evidence shows high response rates (82% ORR) to PARP inhibitors 4
• HRD-related alterations: Associated with favorable response to platinum-based chemotherapy (HR 0.31 for PFS) 6

Additional Considerations

4. UGT1A1 Genotyping

• Critical context for sacituzumab intolerance 7.
• Sacituzumab's active metabolite (SN-38) is metabolized via UGT1A1.
• Patients homozygous or heterozygous for UGT1A1*28 allele have increased risk of neutropenia, febrile neutropenia, and anemia.
• Prevalence: 20% of Black/African American, 10% of White, and 2% of East Asian populations are homozygous (*28/*28).
• If intolerance is due to hematologic toxicity, UGT1A1 testing explains the mechanism and confirms the need for alternative therapy.

Clinical Implementation Strategy

Tissue vs. Liquid Biopsy:

• Tumor tissue NGS is preferred as it detects ~93% of germline BRCA1/2 mutations 4.
• If tissue NGS is negative for BRCA1/2 but clinical suspicion is high, perform dedicated germline testing (captures the remaining 7%) 4.
• Plasma ctDNA can be used when tissue is unavailable, but negative results should prompt tissue testing if available.

Timing:

• Do not delay testing—perform NGS early in the metastatic setting 2.
• Most mTNBC patients (90%) harbor at least one somatic mutation detectable by expanded panels 8.
• The median mutation count is 11 per patient (range 3-1668) 9.

Common Pitfalls to Avoid

1. Don't assume sacituzumab failure means no other options exist: 95% of patients have actionable mutations 2.

2. Don't skip germline BRCA testing: Even if tumor NGS is performed, germline testing may be needed for genetic counseling and family risk assessment.

3. Don't test for TROP2 expression: There is insufficient evidence to recommend routine TROP2 testing to guide therapy 1.

4. Don't overlook brain metastases: These patients may have different mutation profiles and treatment responses—BRCA carriers show higher rates of brain metastases (20% vs. 8.3%) 3.

5. Don't forget that TP53 mutations are nearly universal (82-94% in mTNBC) 9, 6 but are not currently actionable—focus on other targets.

Alternative Therapy Selection Based on Mutations

Once mutations are identified:

• BRCA1/2 or PALB2 mutations → PARP inhibitors
• PD-L1 positive → Pembrolizumab + chemotherapy
• TMB-high → Pembrolizumab monotherapy
• HRD alterations → Platinum-based chemotherapy
• NTRK fusions → TRK inhibitors
• PIK3CA/AKT1/PTEN → Consider capivasertib (if hormone receptor status allows)

The goal is to identify these alternatives before the patient's performance status deteriorates, as genomic mutation-driven therapy requires adequate functional capacity to benefit 2.